Compare Amylx Pharmaceuticals Inc (AMLX) vs BlackBerry Limited (BB) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

BlackBerry (BB) trades at $10.97, down 4.02% today, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights strong QNX growth in automotive and robotics sectors, though valuation metrics remain elevated with P/E at 109.7 and P/S at 11.26.

The outlook is cautiously optimistic as BlackBerry's turnaround gains traction with improved cash flow and QNX momentum. Key risks include execution challenges amid rich valuation and competitive pressures. Analyst consensus leans neutral with 85.7% hold ratings and $10.50 price target, suggesting limited near-term upside from current levels.